Sotera Health (SHC)
Sotera Health on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as services-misc health & allied services, nec.
14.7M
Short interest
settlement 2026-09-30
6.8
Days to cover
-0.5 days vs prior
63.6%
Short share of volume
2026-10-23
7,939
Fails to deliver
settlement 2026-09-24
Tue 3 Nov
Next earnings
estimated date
-$24.0M
Insider flow, 90 days
0 buys, 3 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in SHC is 14,748,380 shares, up 2,788,493 shares over the last month. Over the last 48 readings it ranged from 6,401,207 shares (15 January 2026) to 19,700,874 shares (15 May 2026). At the reported average volume of 2.2M shares a day that is 6.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/shc" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 14,748,380 | +20.2% | 2,184,596 | 6.75 |
| 2026-09-15 | 12,272,393 | +2.6% | 1,693,378 | 7.25 |
| 2026-08-31 | 11,959,887 | -1.3% | 2,611,197 | 4.58 |
| 2026-08-14 | 12,116,521 | -15.8% | 2,859,417 | 4.24 |
| 2026-07-31 | 14,381,320 | -9.2% | 2,996,602 | 4.80 |
| 2026-07-15 | 15,837,315 | -1.1% | 2,903,124 | 5.46 |
| 2026-06-30 | 16,020,278 | -9.1% | 2,681,880 | 5.97 |
| 2026-06-15 | 17,628,756 | -6.5% | 2,488,343 | 7.08 |
| 2026-05-29 | 18,844,871 | -4.3% | 2,704,150 | 6.97 |
| 2026-05-15 | 19,700,874 | +38.2% | 5,980,868 | 3.29 |
| 2026-04-30 | 14,254,525 | +11.3% | 2,314,384 | 6.16 |
| 2026-04-15 | 12,807,626 | +5.8% | 2,852,652 | 4.49 |
| 2026-03-31 | 12,104,859 | +14.8% | 2,896,873 | 4.18 |
| 2026-03-13 | 10,539,768 | +19.4% | 4,435,002 | 2.38 |
| 2026-02-27 | 8,825,205 | +15.1% | 1,605,146 | 5.50 |
| 2026-02-13 | 7,669,545 | +15.0% | 1,606,251 | 4.77 |
| 2026-01-30 | 6,667,644 | +4.2% | 1,356,381 | 4.92 |
| 2026-01-15 | 6,401,207 | -9.0% | 2,160,747 | 2.96 |
| 2025-12-31 | 7,033,415 | -1.5% | 1,838,916 | 3.82 |
| 2025-12-15 | 7,138,895 | -6.3% | 2,745,129 | 2.60 |
| 2025-11-28 | 7,621,320 | -1.6% | 2,103,893 | 3.62 |
| 2025-11-14 | 7,742,768 | +8.3% | 4,518,483 | 1.71 |
| 2025-10-31 | 7,150,268 | -1.4% | 1,134,254 | 6.30 |
| 2025-10-15 | 7,248,497 | -0.6% | 1,239,589 | 5.85 |
| 2025-09-30 | 7,291,907 | -17.0% | 1,590,279 | 4.59 |
| 2025-09-15 | 8,783,457 | -22.6% | 3,509,151 | 2.50 |
| 2025-08-29 | 11,342,527 | -17.5% | 1,458,085 | 7.78 |
| 2025-08-15 | 13,751,828 | -2.7% | 1,930,039 | 7.13 |
| 2025-07-31 | 14,131,996 | +3.3% | 1,048,107 | 13.48 |
| 2025-07-15 | 13,682,732 | +11.2% | 873,346 | 15.67 |
| 2025-06-30 | 12,303,630 | -0.1% | 1,409,126 | 8.73 |
| 2025-06-13 | 12,318,287 | -1.1% | 1,566,987 | 7.86 |
| 2025-05-30 | 12,460,425 | -5.8% | 845,271 | 14.74 |
| 2025-05-15 | 13,233,021 | +4.9% | 1,231,425 | 10.75 |
| 2025-04-30 | 12,612,573 | +0.7% | 1,033,861 | 12.20 |
| 2025-04-15 | 12,522,727 | +11.0% | 1,799,609 | 6.96 |
| 2025-03-31 | 11,279,159 | +16.0% | 1,068,291 | 10.56 |
| 2025-03-14 | 9,722,720 | +12.6% | 1,449,554 | 6.71 |
| 2025-02-28 | 8,637,059 | +2.8% | 1,411,475 | 6.12 |
| 2025-02-14 | 8,403,395 | +10.9% | 713,020 | 11.79 |
| 2025-01-31 | 7,574,205 | +9.8% | 896,636 | 8.45 |
| 2025-01-15 | 6,900,123 | -1.3% | 860,146 | 8.02 |
| 2024-12-31 | 6,987,447 | +5.6% | 1,165,782 | 5.99 |
| 2024-12-13 | 6,614,331 | -18.7% | 1,245,397 | 5.31 |
| 2024-11-29 | 8,133,766 | -6.3% | 2,326,153 | 3.50 |
| 2024-11-15 | 8,685,015 | -3.2% | 1,153,092 | 7.53 |
| 2024-10-31 | 8,975,186 | -11.1% | 659,291 | 13.61 |
| 2024-10-15 | 10,098,043 | -13.7% | 991,874 | 10.18 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 23 October 2026, the short share of SHC volume is 63.6%, down 9.6 points over the last five sessions. Over the last 30 readings it ranged from 42.5% (30 September 2026) to 82.4% (14 September 2026). The latest reading is in line with the 30-session average of 64.0%, on 645K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 410K | 645K | 63.6% | 200 |
| 2026-10-22 | 471K | 780K | 60.4% | 2 |
| 2026-10-21 | 484K | 862K | 56.2% | 9 |
| 2026-10-20 | 392K | 518K | 75.7% | 3,552 |
| 2026-10-19 | 405K | 542K | 74.9% | 25,425 |
| 2026-10-16 | 338K | 462K | 73.2% | 0 |
| 2026-10-15 | 413K | 678K | 60.9% | 0 |
| 2026-10-14 | 493K | 779K | 63.2% | 0 |
| 2026-10-13 | 259K | 475K | 54.5% | 83 |
| 2026-10-12 | 291K | 460K | 63.2% | 0 |
| 2026-10-09 | 264K | 521K | 50.7% | 21 |
| 2026-10-08 | 361K | 497K | 72.6% | 27,394 |
| 2026-10-07 | 260K | 577K | 45.0% | 61 |
| 2026-10-06 | 303K | 405K | 74.6% | 10,421 |
| 2026-10-05 | 256K | 495K | 51.7% | 19 |
| 2026-10-02 | 387K | 645K | 60.0% | 102 |
| 2026-10-01 | 377K | 525K | 71.8% | 142 |
| 2026-09-30 | 203K | 477K | 42.5% | 0 |
| 2026-09-29 | 393K | 524K | 74.9% | 1 |
| 2026-09-28 | 299K | 479K | 62.4% | 56 |
| 2026-09-25 | 269K | 434K | 61.9% | 0 |
| 2026-09-24 | 195K | 379K | 51.4% | 6 |
| 2026-09-23 | 427K | 621K | 68.8% | 47 |
| 2026-09-22 | 356K | 588K | 60.6% | 0 |
| 2026-09-21 | 431K | 621K | 69.4% | 0 |
| 2026-09-18 | 532K | 776K | 68.5% | 1 |
| 2026-09-17 | 517K | 799K | 64.7% | 3 |
| 2026-09-16 | 657K | 1.0M | 63.5% | 0 |
| 2026-09-15 | 618K | 807K | 76.6% | 42 |
| 2026-09-14 | 495K | 602K | 82.4% | 95 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 24 September 2026, the fails-to-deliver balance in SHC is 7,939 shares, up 6,807 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (14 August 2026) to 196,502 shares (23 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-24 | 7,939 | $18.29 | $145K |
| 2026-08-24 | 1,132 | $19.57 | $22K |
| 2026-08-14 | 1 | $19.02 | $19 |
| 2026-08-06 | 6 | $17.98 | $108 |
| 2026-07-30 | 513 | $17.53 | $9K |
| 2026-07-16 | 1,619 | $18.15 | $29K |
| 2026-06-30 | 29,016 | $17.52 | $508K |
| 2026-06-26 | 60 | $17.10 | $1K |
| 2026-06-25 | 485 | $16.69 | $8K |
| 2026-06-23 | 16,614 | $15.74 | $262K |
| 2026-06-03 | 18 | $15.02 | $270 |
| 2026-05-19 | 2,051 | $15.35 | $31K |
| 2026-05-15 | 1,377 | $15.49 | $21K |
| 2026-05-13 | 3,417 | $15.63 | $53K |
| 2026-05-12 | 506 | $15.43 | $8K |
| 2026-05-11 | 506 | $15.78 | $8K |
| 2026-04-28 | 5 | $15.81 | $79 |
| 2026-04-20 | 6,953 | $16.30 | $113K |
| 2026-03-26 | 24,948 | $13.70 | $342K |
| 2026-03-23 | 196,502 | $13.50 | $2.7M |
| 2026-03-09 | 551 | $14.66 | $8K |
| 2026-03-06 | 124,100 | $15.06 | $1.9M |
| 2026-02-11 | 36 | $17.46 | $629 |
| 2026-02-06 | 8 | $17.40 | $139 |
| 2026-02-03 | 9,222 | $18.30 | $169K |
| 2026-02-02 | 9,986 | $18.12 | $181K |
| 2026-01-09 | 1,142 | $18.81 | $21K |
| 2026-01-08 | 8,482 | $18.80 | $159K |
| 2025-12-22 | 1,656 | $17.17 | $28K |
| 2025-12-12 | 5 | $16.90 | $85 |
Insider trades
SEC Form 4, newest first. JSONInsiders at SHC reported 3 open-market sells worth $24.0M in the last 90 days and no open-market buys. Latest filing: Petras Michael B. Jr. (Executive Chairman) on 2026-08-17.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Petras Michael B. Jr. | Executive Chairman | Sell | 850K | $18.50 | $15.7M | 4.0M |
| 2026-08-17 | Petras Michael B. Jr. | Executive Chairman | Sell | 295K | $18.50 | $5.4M | 398K |
| 2026-08-07 | Rutz Michael P | President of Sterigenics | Sell | 150K | $18.84 | $2.8M | 334K |
| 2026-08-05 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 11K | $17.98 | $203K | 217K |
| 2026-05-26 | SHADER ALTON | Chief Executive Officer | Grant | 204K | $0.00 | $0 | 580K |
| 2026-05-26 | SHADER ALTON | Chief Executive Officer | Grant | 376K | $0.00 | $0 | 376K |
| 2026-05-22 | Wheadon David E. | Director | Grant | 15K | $0.00 | $0 | 90K |
| 2026-05-22 | Simon, Christopher | Director | Grant | 15K | $0.00 | $0 | 34K |
| 2026-05-22 | PETRELLA VINCENT K | Director | Grant | 15K | $0.00 | $0 | 96K |
| 2026-05-22 | Neary James | Director | Grant | 15K | $0.00 | $0 | 96K |
| 2026-05-22 | Kyle Richard G | Director | Grant | 15K | $0.00 | $0 | 15K |
| 2026-05-22 | Krause Kenneth D. | Director | Grant | 15K | $0.00 | $0 | 15K |
| 2026-05-22 | Klee Ann R. | Director | Grant | 15K | $0.00 | $0 | 141K |
| 2026-05-22 | Flynn Karen | Director | Grant | 15K | $0.00 | $0 | 54K |
| 2026-05-22 | Chen Ruoxi | Director | Grant | 15K | $0.00 | $0 | 96K |
| 2026-05-22 | CUNNINGHAM SEAN LAURENCE | Director | Grant | 15K | $0.00 | $0 | 96K |
| 2026-05-13 | GTCR FUND XI/C LP | Director,TenPercentOwner | Sell | 12.7M | $15.17 | $193.2M | 0 |
| 2026-05-13 | Warburg Pincus XI, L.P. | Director,TenPercentOwner | Sell | 19.1M | $15.17 | $289.8M | 0 |
| 2026-05-13 | Warburg Pincus (Cayman) XI, L.P. | Director,TenPercentOwner | Sell | 19.1M | $15.17 | $289.8M | 0 |
| 2026-05-13 | GTCR INVESTMENT XI LLC | Director, 10% owner | Sell | 12.7M | $15.17 | $193.2M | 0 |
| 2026-05-13 | WARBURG PINCUS & CO. | Director, 10% owner | Sell | 19.1M | $15.17 | $289.8M | 0 |
| 2026-03-31 | DIMITRIEF ALEXANDER | Former SVP, GC and Sec. | Tax withholding | 8K | $14.34 | $114K | 312K |
| 2026-03-06 | GTCR CO-INVEST XI LP | Director,TenPercentOwner | Sell | 10.0M | $15.27 | $152.7M | 12.7M |
| 2026-03-06 | Warburg Pincus Partners II, L.P. | Director,TenPercentOwner | Sell | 15.0M | $15.27 | $229.1M | 19.1M |
| 2026-03-06 | Warburg Pincus Partners GP LLC | Director,TenPercentOwner | Sell | 15.0M | $15.27 | $229.1M | 19.1M |
| 2026-03-06 | GTCR INVESTMENT XI LLC | Director, 10% owner | Sell | 10.0M | $15.27 | $152.7M | 12.7M |
| 2026-03-06 | WARBURG PINCUS & CO. | Director, 10% owner | Sell | 15.0M | $15.27 | $229.1M | 19.1M |
| 2026-03-02 | Rutz Michael P | President of Sterigenics | Exercise or conversion | 15K | price not stated in the filing | not stated | 457K |
| 2026-03-02 | Rutz Michael P | President of Sterigenics | Tax withholding | 17K | $15.91 | $278K | 439K |
| 2026-03-02 | Rutz Michael P | President of Sterigenics | Grant | 45K | $0.00 | $0 | 484K |
| 2026-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 24K | $15.91 | $382K | 178K |
| 2026-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 8K | $15.91 | $131K | 169K |
| 2026-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Grant | 59K | $0.00 | $0 | 229K |
| 2026-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Exercise or conversion | 18K | price not stated in the filing | not stated | 201K |
| 2026-03-02 | DIMITRIEF ALEXANDER | SVP, General Counsel and Sec. | Exercise or conversion | 17K | price not stated in the filing | not stated | 344K |
| 2026-03-02 | DIMITRIEF ALEXANDER | SVP, General Counsel and Sec. | Tax withholding | 24K | $15.91 | $376K | 320K |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Exercise or conversion | 90K | price not stated in the filing | not stated | 571K |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 79K | $15.91 | $1.3M | 452K |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 40K | $15.91 | $629K | 531K |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Grant | 240K | $0.00 | $0 | 692K |
| 2026-03-02 | Rutz Michael P | President of Sterigenics | Tax withholding | 4K | $15.91 | $72K | 442K |
| 2026-03-02 | Rutz Michael P | President of Sterigenics | Tax withholding | 4K | $15.91 | $59K | 446K |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 40K | $15.91 | $641K | 481K |
| 2026-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 31K | $15.91 | $499K | 521K |
| 2026-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 6K | $15.91 | $96K | 184K |
| 2026-03-02 | DIMITRIEF ALEXANDER | SVP, General Counsel and Sec. | Tax withholding | 8K | $15.91 | $126K | 327K |
| 2025-12-08 | Petras Michael B. Jr. | Chairman & CEO | Sell | 39K | $16.45 | $646K | 0 |
| 2025-12-08 | Petras Michael B. Jr. | Chairman & CEO | Sell | 395K | $16.45 | $6.5M | 4.8M |
| 2025-12-08 | Petras Michael B. Jr. | Chairman & CEO | Sell | 316K | $16.45 | $5.2M | 553K |
| 2025-12-03 | GTCR FUND XI/A LP | Director,TenPercentOwner | Sell | 6.5M | $16.33 | $105.8M | 22.7M |
| 2025-12-03 | Warburg Pincus Partners GP LLC | Director,TenPercentOwner | Sell | 9.7M | $16.33 | $158.7M | 34.1M |
| 2025-12-03 | WARBURG PINCUS LLC | Director,TenPercentOwner | Sell | 9.7M | $16.33 | $158.7M | 34.1M |
| 2025-12-03 | WARBURG PINCUS & CO. | Director, 10% owner | Sell | 9.7M | $16.33 | $158.7M | 34.1M |
| 2025-12-03 | GTCR INVESTMENT XI LLC | Director, 10% owner | Sell | 6.5M | $16.33 | $105.8M | 22.7M |
| 2025-11-10 | Warburg Pincus Partners II, L.P. | Director | Sell | 18.0M | $15.65 | $281.7M | 43.8M |
| 2025-11-10 | Warburg Pincus Private Equity XI-C, L.P. | Director,TenPercentOwner | Sell | 18.0M | $15.65 | $281.7M | 43.8M |
| 2025-11-10 | GTCR FUND XI/A LP | Director,TenPercentOwner | Sell | 12.0M | $15.65 | $187.8M | 29.2M |
| 2025-11-10 | GTCR INVESTMENT XI LLC | Director, 10% owner | Sell | 12.0M | $15.65 | $187.8M | 29.2M |
| 2025-11-10 | WARBURG PINCUS & CO. | Director, 10% owner | Sell | 18.0M | $15.65 | $281.7M | 43.8M |
| 2025-09-05 | WARBURG PINCUS & CO. | Director,TenPercentOwner | Sell | 12.0M | $15.11 | $181.3M | 61.8M |
| 2025-09-05 | Warburg Pincus XI-C, LLC | Director,TenPercentOwner | Sell | 12.0M | $15.11 | $181.3M | 61.8M |
| 2025-09-05 | WARBURG PINCUS & CO. | Director, 10% owner | Sell | 12.0M | $15.11 | $181.3M | 61.8M |
| 2025-09-05 | GTCR INVESTMENT XI LLC | Director, 10% owner | Sell | 8.0M | $15.11 | $120.9M | 41.2M |
| 2025-08-22 | Rutz Michael P | President of Sterigenics | Sell | 127K | $16.38 | $2.1M | 450K |
| 2025-08-05 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 12K | $11.19 | $129K | 190K |
| 2025-05-22 | Simon, Christopher | Director | Grant | 19K | $0.00 | $0 | 19K |
| 2025-05-22 | Chen Ruoxi | Director | Grant | 19K | $0.00 | $0 | 81K |
| 2025-05-22 | CUNNINGHAM SEAN LAURENCE | Director | Grant | 19K | $0.00 | $0 | 81K |
| 2025-05-22 | Klee Ann R. | Director | Grant | 19K | $0.00 | $0 | 126K |
| 2025-05-22 | MIHAS CONSTANTINE S | Director | Grant | 19K | $0.00 | $0 | 81K |
| 2025-05-22 | Neary James | Director | Grant | 19K | $0.00 | $0 | 81K |
| 2025-05-22 | PETRELLA VINCENT K | Director | Grant | 19K | $0.00 | $0 | 81K |
| 2025-05-22 | Wheadon David E. | Director | Grant | 19K | $0.00 | $0 | 75K |
| 2025-05-22 | Knauss Robert Brown | Director | Grant | 19K | $0.00 | $0 | 55K |
| 2025-05-22 | Flynn Karen | Director | Grant | 19K | $0.00 | $0 | 39K |
| 2025-03-03 | DIMITRIEF ALEXANDER | SVP, General Counsel and Sec. | Grant | 56K | $0.00 | $0 | 335K |
| 2025-03-03 | Lyons Jonathan M. | Sr. Vice President, CFO | Grant | 37K | $0.00 | $0 | 201K |
| 2025-03-03 | Lyons Jonathan M. | Sr. Vice President, CFO | Grant | 60K | $0.00 | $0 | 164K |
| 2025-03-03 | Rutz Michael P | President of Sterigenics | Grant | 49K | $0.00 | $0 | 577K |
| 2025-03-03 | Petras Michael B. Jr. | Chairman & CEO | Grant | 299K | $0.00 | $0 | 869K |
| 2025-03-02 | DIMITRIEF ALEXANDER | SVP, General Counsel and Sec. | Tax withholding | 8K | $12.47 | $102K | 279K |
| 2025-03-02 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 6K | $12.47 | $81K | 104K |
| 2025-03-02 | Rutz Michael P | President of Sterigenics | Tax withholding | 5K | $12.47 | $67K | 528K |
| 2025-03-02 | Rutz Michael P | President of Sterigenics | Tax withholding | 4K | $12.47 | $52K | 534K |
| 2025-03-02 | Rutz Michael P | President of Sterigenics | Tax withholding | 4K | $12.47 | $46K | 538K |
| 2025-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 28K | $12.47 | $349K | 643K |
| 2025-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 32K | $12.47 | $397K | 611K |
| 2025-03-02 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 41K | $12.47 | $511K | 570K |
| 2024-11-22 | Petras Michael B. Jr. | Chairman & CEO | Gift | 39K | $0.00 | $0 | 5.2M |
| 2024-11-22 | Petras Michael B. Jr. | Chairman & CEO | Gift | 39K | $0.00 | $0 | 39K |
| 2024-11-20 | Rutz Michael P | President of Sterigenics | Tax withholding | 3K | $13.21 | $38K | 542K |
| 2024-11-20 | Petras Michael B. Jr. | Chairman & CEO | Tax withholding | 29K | $13.21 | $386K | 670K |
| 2024-09-10 | Petras Michael B. Jr. | Chairman & CEO | Gift | 200K | $0.00 | $0 | 5.3M |
| 2024-09-06 | GTCR PARTNERS XI/A&C LP | Director,TenPercentOwner | Sell | 10.0M | $15.03 | $150.3M | 49.2M |
| 2024-09-06 | Bull Holdco L.P. | Director,TenPercentOwner | Sell | 15.0M | $15.03 | $225.4M | 73.8M |
| 2024-09-06 | Warburg Pincus Private Equity XI-C, L.P. | Director,TenPercentOwner | Sell | 15.0M | $15.03 | $225.4M | 73.8M |
| 2024-08-05 | Lyons Jonathan M. | Sr. Vice President, CFO | Tax withholding | 8K | $14.22 | $109K | 110K |
| 2024-05-24 | Chen Ruoxi | Director | Grant | 20K | $0.00 | $0 | 62K |
| 2024-05-24 | CUNNINGHAM SEAN LAURENCE | Director | Grant | 20K | $0.00 | $0 | 62K |
| 2024-05-24 | Donnini David | Director | Grant | 20K | $0.00 | $0 | 62K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON6 Form 144 notices on file for SHC worth $284.9M at the prices reported; 1 in the last 90 days worth $2.8M. Latest: Rutz Michael P filed on 2026-08-07 to sell 150,000 shares ($2.8M) from 2026-08-07.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-07 | Rutz Michael POfficer | 150K | $2.8M | 0.053% | 2026-08-07 | Charles Schwab Corp. |
| 2025-12-08 | Michael B. Petras, Jr.Chairman, CEO | 750K | $12.6M | 0.264% | 2025-12-08 | J.P. Morgan Securities LLC |
| 2025-12-04 | GTCR FUND XI/C LPOwner | 1.3M | $21.2M | 28.502% | 2025-12-03 | Goldman Sachs & Co. LLC |
| 2025-12-03 | WARBURG PINCUS LLCAffiliate | 9.7M | $163.7M | 3.421% | 2025-12-03 | Goldman Sachs & Co. LLC |
| 2025-12-03 | GTCR FUND XI/A LPOwner | 5.1M | $84.0M | 28.502% | 2025-12-03 | Goldman Sachs & Co. LLC |
| 2025-12-03 | GTCR CO-INVEST XI LPOwner | 41K | $673K | 28.502% | 2025-12-03 | Goldman Sachs & Co. LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON17 holders report 5% or more of SHC in their latest filing, all on Schedule 13G (passive). The largest reported stake is Sessa Capital IM, L.P. at 9.5% of the class (27,050,000 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-09 | 13G/Ano. 1 | Sachem Head GP LLCother entity | 0 | 0.0% | 2026-10-09 |
| 2026-10-09 | 13G/Ano. 1 | Uncas GP LLCother entity | 0 | 0.0% | 2026-10-09 |
| 2026-10-09 | 13G/Ano. 1 | Sachem Head Capital Management LPinvestment adviser | 0 | 0.0% | 2026-10-09 |
| 2026-10-09 | 13G/Ano. 1 | Ferguson Scott D.individual | 0 | 0.0% | 2026-10-09 |
| 2026-08-14 | 13G/Ano. 2 | Sculptor Capital II LPinvestment adviser | 24.0M | 8.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Sculptor Capital Holding Corpcorporation | 24.0M | 8.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Sculptor Capital LPinvestment adviser | 24.0M | 8.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Sculptor Capital Holding II LLCcorporation | 24.0M | 8.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Sculptor Capital Management, Inc.corporation | 24.0M | 8.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Sculptor Master Fund, Ltd.corporation | 24.0M | 8.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Sessa Capital IM, L.P.investment adviser, partnership | 27.1M | 9.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | John Petryparent holding company, individual | 27.1M | 9.5% | 2026-06-30 |
| 2026-07-30 | 13G/Ano. 2 | BlackRock, Inc.parent holding company | 23.8M | 8.4% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 7 | GTCR CO-INVEST XI LPpartnership | 0 | 0.0% | 2026-05-13 |
| 2026-05-15 | 13G/Ano. 7 | GTCR FUND XI/C LPpartnership | 0 | 0.0% | 2026-05-13 |
| 2026-05-15 | 13G/Ano. 7 | GTCR FUND XI/A LPpartnership | 0 | 0.0% | 2026-05-13 |
| 2026-05-15 | 13G/Ano. 7 | GTCR INVESTMENT XI LLCother entity | 0 | 0.0% | 2026-05-13 |
| 2026-05-15 | 13G/Ano. 7 | GTCR PARTNERS XI/A&C LPpartnership | 0 | 0.0% | 2026-05-13 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus (Bermuda) Private Equity GP Ltd.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus LLCother entity | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus Partners II (Cayman), L.P.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus XI-C, LLCother entity | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus (Cayman) XI, L.P.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus Partners GP LLCother entity | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus Partners II, L.P.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | WP Global LLCother entity | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus XI, L.P.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Bull Co-Invest L.P.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus Private Equity XI-C, L.P.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus Private Equity XI-B, L.P.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus XI Partners, L.P.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | Warburg Pincus Private Equity XI, L.P.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | WP XI Partners, L.P.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-05-15 | 13G/Ano. 6 | WARBURG PINCUS & CO.partnership | 0 | 0.0% | 2026-03-06 |
| 2026-03-27 | 13G/Ano. 3 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G | Sessa Capital IM GP, LLCother entity | 20.6M | 7.2% | 2025-12-31 |
| 2026-02-17 | 13G | Sessa Capital GP, LLCother entity | 20.6M | 7.2% | 2025-12-31 |
| 2026-02-17 | 13G | Sessa Capital (Master), L.P.partnership | 15.9M | 5.6% | 2025-12-31 |
| 2026-02-17 | 13G | Sessa Capital Special Opportunity Fund II, L.P.partnership | 4.6M | 1.6% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | Darsana Capital GP LLCparent holding company, other entity | 25.0M | 8.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Darsana Master Fund LPpartnership | 25.0M | 8.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Darsana Capital Partners LPinvestment adviser, partnership | 25.0M | 8.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Anand Desaiparent holding company, individual | 25.0M | 8.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Darsana Capital Partners GP LLCparent holding company, other entity | 25.0M | 8.8% | 2025-09-30 |
13F holders
Tracked managers holding SHC at their latest 13F. JSON6 of the 30 tracked managers held SHC at their latest 13F, $332.7M in total at quarter-end prices. AQR Capital Management is the largest at $186.4M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 10.7M | $186.4M | 0.07% | +4.0M |
| Greenlight Capital (DME Capital) | 2026-06-30 | 4.1M | $73.4M | 1.88% | +2.1M |
| Citadel Advisors | 2026-06-30 | 2.0M | $35.6M | 0.00% | +1.3M |
| Millennium Management | 2026-06-30 | 1.9M | $34.3M | 0.01% | +1.6M |
| Two Sigma Investments | 2026-06-30 | 152K | $2.7M | 0.00% | +38K |
| Bridgewater Associates | 2026-06-30 | 19K | $342K | 0.00% | -676K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Sotera Health reported revenue of $321.4M, up 9.2% from the same quarter a year earlier, and net income of $53.6M (0.19 diluted EPS). In FY 2025 it generated $287.2M of operating cash flow. As of 2026-06-30, cash was $356.7M against $2.14B of debt.
- Cash
- $356.7M
- Debt
- $2.14B
- Equity
- $665.6M
- Total assets
- $3.31B
- Shares outstanding
- 285,374,795
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $321.4M | $53.6M | 16.7% | 0.19 |
| Q1 FY 2026 | 2026-03-31 | $280.0M | $26.6M | 9.5% | 0.09 |
| Q4 FY 2025derived | 2025-12-31 | $303.4M | $34.8M | 11.5% | n/a |
| Q3 FY 2025 | 2025-09-30 | $311.3M | $48.4M | 15.5% | 0.17 |
| Q2 FY 2025 | 2025-06-30 | $294.3M | $8.0M | 2.7% | 0.03 |
| Q1 FY 2025 | 2025-03-31 | $254.5M | -$13.3M | -5.2% | -0.05 |
| Q4 FY 2024derived | 2024-12-31 | $290.2M | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $285.5M | $17.0M | 6.0% | 0.06 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1.16B | $77.9M | $287.2M | $138.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $1.10B | $44.4M | $224.2M | $179.1M | n/a | n/a |
| FY 2023 | 2023-12-31 | $1.05B | $51.4M | -$147.7M | $215.0M | n/a | n/a |
| FY 2022 | 2022-12-31 | $1.00B | -$233.6M | $278.0M | $182.4M | $0 | n/a |
| FY 2021 | 2021-12-31 | $931.5M | $116.9M | $281.5M | $102.2M | $0 | $0 |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.
What this page is
Sotera Health in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Sotera Health (SHC), SEC CIK 1822479, listed on Nasdaq, classified by the SEC as services-misc health & allied services, nec. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-24.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-07.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-09.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-17.JSON and CSV
- Company record
- EDGAR filing index for CIK 1822479Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as services-misc health & allied services, nec
Other company pages
Datasets
Frequently Asked Questions
How much of SHC is sold short?
14,748,380 shares were held short at the 2026-09-30 settlement, 6.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is SHC's daily short volume?
On 2026-10-23, 410,393 of the 645,406 SHC shares reported to FINRA were sold short, 63.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does SHC have fails to deliver?
The SEC's latest file shows 7,939 SHC shares failed to deliver at settlement 2026-09-24. Fails are reported per settlement date and published twice a month with a lag.
Are SHC insiders buying or selling?
Insiders at SHC reported 3 open-market sells worth $24.0M in the last 90 days and no open-market buys. Latest filing: Petras Michael B. Jr. (Executive Chairman) on 2026-08-17.
Have SHC insiders filed to sell?
6 Form 144 notices on file for SHC worth $284.9M at the prices reported; 1 in the last 90 days worth $2.8M. Latest: Rutz Michael P filed on 2026-08-07 to sell 150,000 shares ($2.8M) from 2026-08-07.
Who owns 5% or more of SHC?
17 holders report 5% or more of SHC in their latest filing, all on Schedule 13G (passive). The largest reported stake is Sessa Capital IM, L.P. at 9.5% of the class (27,050,000 shares), filed 2026-08-14 for an event on 2026-06-30.
What did SHC report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Sotera Health reported revenue of $321.4M, up 9.2% from the same quarter a year earlier, and net income of $53.6M (0.19 diluted EPS). In FY 2025 it generated $287.2M of operating cash flow. As of 2026-06-30, cash was $356.7M against $2.14B of debt.
Which tracked 13F managers own SHC?
6 of the 30 tracked 13F managers held SHC shares at their latest filing, $332.7M in all. The largest: Cliff Asness's AQR Capital Management (10.7M shares, $186.4M), David Einhorn's Greenlight Capital (DME Capital) (4.1M shares, $73.4M), Ken Griffin's Citadel Advisors (2.0M shares, $35.6M), Izzy Englander's Millennium Management (1.9M shares, $34.3M), Two Sigma Investments (152K shares, $2.7M), Ray Dalio's Bridgewater Associates (19K shares, $342K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.